TENXNASDAQHealthcare

TENAX THERAPEUTICS INC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$1.69

+3.68%

Alpha Vantage · 11/6/2026

Industry: BiotechnologyCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze TENX free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

-9.1%

3 months

+22.9%

6 months

-85.5%

1 year

-75.6%

Year to date

-86.1%

52-week range

$1.36 – $18.32

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$77M

P/E

-1.2

P/B

0.7

P/S

—

Revenue

Net income

-$65.76M

Diluted EPS

-1.39

Gross margin

—

Net margin

—

Return on equity

-60.60%

Total debt

Cash

$113.73M

Free cash flow

-$49.35M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$0	-$16.7M	—	—	-$12.48M
Jun 30, 2026	$0	-$17.8M	—	—	-$14.15M
Mar 31, 2026	$0	-$15.72M	—	—	-$9.31M
Dec 31, 2025	$0	-$15.54M	—	—	-$13.42M
Sep 30, 2025	$0	-$15.8M	—	—	-$9.16M
Jun 30, 2025	$0	-$10.85M	—	—	-$6.26M
Mar 31, 2025	$0	-$10.41M	—	—	-$6.97M
Dec 31, 2024	$0	-$6.27M	—	—	-$3.53M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent TENX news

All market news

PR Newswire·Nov 4, 202667 signal

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 28, 2026 in Tenax Therapeutics, Inc. Lawsuit - TENX

Levi & Korsinsky, LLP is reminding shareholders of Tenax Therapeutics, Inc. (NASDAQ: TENX) that a lead plaintiff deadline of December 28, 2026, is approaching for a pending securities class action lawsuit. The lawsuit covers shares acquired between November 13, 2023, and August 7, 2026, alleging that Tenax made misleading statements regarding the efficacy and prospects of its drug TNX-103, particularly concerning its Phase 3 LEVEL study which ultimately failed to meet its primary endpoint. Investors who purchased shares during this period may be eligible to recover losses and are encouraged to contact Levi & Korsinsky for an assessment.

Original source